Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy?

Clicks: 16
ID: 282909
2025
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The pivotal role of tumor-draining lymph nodes (TDLNs) in supporting antitumor immunity and serving as sites for cancer metastasis presents a clinical challenge: eliminate tumors while preserving antitumor immune responses. In this article, we explore the initiation of tumor-specific immune responses within lymph nodes (LNs), the immunocompromised microenvironment induced by tumors within LNs, and the crucial involvement of TDLNs in immunotherapy. Additionally, we examine the clinical prospects of modifying surgical procedures or therapy sequences to enhance the efficacy of cancer treatment.
Reference Key
von renesse2025tumordraining Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors von Renesse, Janusz; Lin, Mei-Chun; Ho, Ping-Chih
Journal Trends in cancer
Year 2025
DOI 10.1016/j.trecan.2025.04.008
URL
Keywords
neoadjuvant immunotherapy immune checkpoint blockade (icb) lymph node preservation progenitor-exhausted t (tpex) cells tumor-draining lymph node (tdln) tumor-specific memory t (ttsm) cell

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.